{"id":"W4310295951","doi":"10.1177/13524585221137502","title":"Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry","year":2022,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"EMD Serono; Multiple Sclerosis Society; Università di Catania; Multiple Sclerosis Society of Canada; H. Lundbeck A/S; International Progressive MS Alliance; Universität Basel; Merck KGaA; Univerzita Karlova v Praze; Biogen; Celgene; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; GlaxoSmithKline; Sanofi; Fondation Brain Canada; Pfizer","keywords":"Teriflunomide; Cladribine; Fingolimod; Medicine; Discontinuation; Multiple sclerosis; Dimethyl fumarate; Internal medicine; Hazard ratio; Clinical trial; Confidence interval; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00216646,0.0007159424,0.00172588,0.0004570308,0.001736159,0.0001365256,0.0006309844,0.0001401586,0.0002318963],"category_scores_gemma":[0.00388658,0.0006401609,0.0008600579,0.0006744722,0.0004377587,0.0003853008,0.0005408541,0.001056644,0.00001633397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001364096,"about_ca_system_score_gemma":0.0004947805,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001162736,"about_ca_topic_score_gemma":0.0001611176,"domain_scores_codex":[0.9932404,0.001260279,0.00139154,0.001120313,0.001810445,0.001176995],"domain_scores_gemma":[0.9918407,0.004380808,0.001005213,0.001043912,0.0008105086,0.0009189264],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.227725,0.005869907,0.1702821,0.0004520862,0.005032751,0.00007757764,0.002584788,0.01101897,0.5601115,0.00001279465,0.007761049,0.009071444],"study_design_scores_gemma":[0.1280306,0.002656715,0.8056517,0.002112658,0.001130635,0.00001281319,0.002477142,0.02045625,0.0336315,0.00004030399,0.003028112,0.0007715067],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825726,0.002008931,0.000983095,0.0003709899,0.001070607,0.003019604,0.009710338,0.0001161471,0.0001477048],"genre_scores_gemma":[0.9917329,0.0004726349,0.005121742,0.00009662444,0.0004548359,0.001072818,0.0007749946,0.0001320594,0.0001413707],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6353697,"threshold_uncertainty_score":0.9996049,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2799543506146697,"score_gpt":0.3646852724158959,"score_spread":0.08473092180122616,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}